The Antiinflammatory Cytokine Interleukin-1 Receptor Antagonist Protects from High-Fat Diet-Induced Hyperglycemia
209
TL;DR: The results show that IL-1Ra improves beta-cell survival and function, and support the potential role for IL-2Ra in the treatment of diabetes, and show further mechanisms of the protective role of IL- 1Ra on the beta- cell.
read more
Abstract: Subclinical inflammation is a recently discovered phenomenon in type 2 diabetes. Elevated cytokines impair beta-cell function and survival. A recent clinical trial shows that blocking IL-1beta signaling by IL-1 receptor antagonist (IL-1Ra) improves beta-cell secretory function in patients with type 2 diabetes. In the present study, we provide further mechanisms of the protective role of IL-1Ra on the beta-cell. IL-1Ra prevented diabetes in vivo in C57BL/6J mice fed a high-fat/high-sucrose diet (HFD) for 12 wk; it improved glucose tolerance and insulin secretion. High-fat diet treatment increased serum levels of free fatty acids and of the adipokines resistin and leptin, which were reduced by IL-1Ra treatment. In addition, IL-1Ra counteracted adiponectin levels, which were decreased by high-fat feeding. Studies on isolated islets revealed that IL-1Ra specifically acted on the beta-cell. IL-1Ra protected islets from HFD treated animals from beta-cell apoptosis, induced beta-cell proliferation, and improved glucose-stimulated insulin secretion. Insulin mRNA was reduced in islets from mice fed a HFD but normalized in the IL-1Ra group. Our results show that IL-1Ra improves beta-cell survival and function, and support the potential role for IL-1Ra in the treatment of diabetes.
read more
Chat with Paper
AI Agents for this Paper
Find similar papers on Google Scholar, PubMed and Arxiv
Write a critical review of this paper
Analyze citations of this paper to find unaddressed research gaps
Citations
NF-κB, inflammation, and metabolic disease.
TL;DR: It is now widely appreciated that chronic low-grade inflammation plays a key role in the initiation, propagation, and development of metabolic diseases, and numerous recent studies have implicated the transcription factor NF-κB in the development of such diseases, thereby further establishing inflammation as a critical factor in their etiology.
1.7K
The cellular and signaling networks linking the immune system and metabolism in disease
Olivia Osborn,Jerrold M. Olefsky +1 more
TL;DR: This work discusses how various networks underlie the etiology of the inflammatory component of insulin resistance, with a particular focus on the central roles of macrophages in adipose tissue and liver.
1.4K
The NLRP3 Inflammasome: A Sensor for Metabolic Danger?
TL;DR: It is proposed that the NLRP3 inflammasome contributes to the pathogenesis of T2DM and gout by functioning as a sensor for metabolic stress.
1.1K
Horror Autoinflammaticus: The Molecular Pathophysiology of Autoinflammatory Disease
TL;DR: An updated classification scheme based on molecular pathophysiology will bring greater clarity to discourse while catalyzing new hypotheses both at the bench and at the bedside, supplanting a clinical classification that has served well but is opaque to the genetic, immunologic, and therapeutic interrelationships now before us.
The Role of Inflammation in Diabetes: Current Concepts and Future Perspectives.
Sotirios Tsalamandris,Alexios S. Antonopoulos,Evangelos Oikonomou,George-Aggelos Papamikroulis,Georgia Vogiatzi,Spyridon Papaioannou,Spyros Deftereos,Dimitris Tousoulis +7 more
TL;DR: In this article, the role of inflammation in both type 1 and type 2 diabetes (T1D and T1D) pathophysiology and associated metabolic disorders, has generated increasing interest in targeting inflammation to improve prevention and control of the disease.
1K
References
Biologic basis for interleukin-1 in disease
TL;DR: This is a lengthy review, with 586 citations chosen to illustrate specific areas of interest rather than a compendium of references, which summarizes what the author considers established or controversial topics linking the biology of IL-1 to mechanisms of disease.
4.6K
β-Cell Deficit and Increased β-Cell Apoptosis in Humans With Type 2 Diabetes
Alexandra E. Butler,Juliette Janson,Susan Bonner-Weir,Robert A. Ritzel,Robert A. Rizza,Peter C. Butler +5 more
TL;DR: Since the major defect leading to a decrease in β-cell mass in type 2 diabetes is increased apoptosis, while new islet formation andβ-cell replication are normal, therapeutic approaches designed to arrest apoptosis could be a significant new development in the management of type 2 Diabetes.
4K
TLR4 links innate immunity and fatty acid–induced insulin resistance
TL;DR: It is suggested that TLR4 is a molecular link among nutrition, lipids, and inflammation and that the innate immune system participates in the regulation of energy balance and insulin resistance in response to changes in the nutritional environment.
Interleukin-1-receptor antagonist in type 2 diabetes mellitus.
Claus M. Larsen,Mirjam V. Faulenbach,Allan Vaag,Allan Vaag,Aage Vølund,Jan A. Ehses,Burkhardt Seifert,Thomas Mandrup-Poulsen,Thomas Mandrup-Poulsen,Marc Y. Donath +9 more
TL;DR: The blockade of interleukin-1 with anakinra improved glycemia and beta-cell secretory function and reduced markers of systemic inflammation.
Islet β cell failure in type 2 diabetes
TL;DR: The major focus of this Review is on the mechanisms of islet beta cell failure in the pathogenesis of obesity-associated type 2 diabetes (T2D).